Eli Lilly announced an increase in its full‑year revenue outlook by five billion dollars, moving the target to between 91 and 92 billion dollars. The company said third‑quarter earnings exceeded analysts’ expectations. Strong demand for its injectable obesity medicines was cited as the primary driver of the better‑than‑expected profit. Revenue for the quarter reached 24.4 billion dollars, above the 22.61 billion dollars reported in the prior period. The lift in the forecast reflects the firm’s confidence in sustaining sales momentum. Analysts had previously projected a lower range for the year’s top line. Reuters reported the figures in a market update.